---
layout: default
title: Deflazacort
parent: 僅模型預測 (L5)
nav_order: 134
evidence_level: L5
indication_count: 0
---

# Deflazacort
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Deflazacort: Drug Repurposing Evaluation – No TxGNN Predictions Available

---

## One-Sentence Summary

Deflazacort (DrugBank ID: DB11921) is an oxazoline-derived glucocorticoid approved in the United States for Duchenne Muscular Dystrophy (DMD) and used in several countries for a range of inflammatory and immune-mediated conditions.
This evidence pack contains **no TxGNN-predicted new indications** for this drug, and critical data gaps — including mechanism of action details and Danish regulatory safety information — prevent a full repurposing assessment at this stage.
A **Hold** decision is recommended until the missing data is obtained and TxGNN predictions are generated.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No approved indications recorded in this evidence pack (drug not registered in Denmark; US indication: Duchenne Muscular Dystrophy) |
| Predicted New Indication | No predictions generated |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 – No predictions or supporting studies returned by this pipeline run |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | **Hold** |

---

## Why No Predictions Are Available

The TxGNN prediction pipeline returned an empty candidates list (`predicted_indications: []`) for this drug. This is an atypical outcome that may arise from one or more of the following:

1. **Knowledge graph coverage**: DrugBank ID DB11921 may not yet be linked to the disease nodes in the TxGNN knowledge graph, resulting in no scored drug–disease pairs being output.
2. **Score threshold filtering**: Prediction scores for all candidate indications may have fallen below the confidence threshold applied during post-processing.
3. **Pipeline status**: The prediction run may have been incomplete at the time this evidence pack was generated (data cut-off: 2026-04-05).

Because no mechanistic data (MOA) was retrieved — marked as a **High-severity** data gap — a narrative explanation of why a predicted indication might be pharmacologically reasonable cannot be provided at this stage.

---

## Denmark Market Information

Deflazacort currently holds **no marketing authorisations** in Denmark (Laegemiddelstyrelsen) and is not listed as a marketed product. There are no national or EMA centralised authorisation records in this evidence pack.

> **Note for reviewers:** Deflazacort is commercially available in other jurisdictions under the brand name **Emflaza** (US-FDA approved, 2017, for DMD in patients aged ≥ 5 years). An EMA/centralised marketing authorisation search should be conducted to confirm whether any pan-European status exists.

---

## Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for full safety information. No local safety data could be extracted from this evidence pack due to the following blocking data gaps:

| Data Gap ID | Item | Severity | Impact |
|-------------|------|----------|--------|
| DG001 | SmPC warnings and contraindications | **Blocking** | Cannot complete S1 safety pre-screening |
| DG002 | Mechanism of action (MOA) | **High** | Cannot perform mechanistic relevance analysis |

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This evaluation cannot advance to the repurposing assessment stage because the TxGNN model returned no predicted indications for Deflazacort, and two unresolved data gaps prevent both safety screening and mechanistic analysis. Proceeding without these inputs would not meet the minimum evidence threshold for a meaningful repurposing recommendation.

**To proceed, the following is needed:**

- **Re-run TxGNN prediction pipeline** for DrugBank ID DB11921 and verify that the drug node is correctly represented in the knowledge graph (confirm node presence in `data/node.csv`)
- **Obtain MOA data** via DrugBank API query for DB11921 (Data Gap DG002 – High severity)
- **Download and parse the SmPC / product monograph** to extract approved warnings, contraindications, and drug interactions (Data Gap DG001 – Blocking severity); source: EMA product page or US FDA label for Emflaza
- **Confirm EMA/centralised authorisation status** to determine whether Deflazacort holds any EU-wide marketing authorisation that may be applicable in Denmark
- **Review Danish special access pathways** (e.g., named-patient or compassionate use) given that Deflazacort is approved in the US for a rare disease (DMD) with unmet need

---

> *This report is generated for research reference purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any therapeutic application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

